Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation

Shu Hsiang Liu, Chiao Ying Lin, Shian Yang Peng, Yung Ming Jeng, Hung Wei Pan, Po Lin Lai, Chao Lien Liu, Hey Chi Hsu

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Annexins (ANXs) are a large group of calcium-binding proteins participating in diverse important biological processes. ANXA10 is the least expressed new member of unknown function. We showed that ANXA10 mRNA was expressed in adult liver and hepatocellular carcinoma (HCC), but not in multiple adult and fetal tissues, cholangiocarcinoma, and several other common carcinomas. Of 182 unifocal primary HCCs, ANXA10 mRNA was dramatically reduced in 121 (66%), and the down-regulation correlated with p53 mutation (P = 0.024), early intrahepatic tumor recurrence (P = 0.0007), and lower 4-year survival (P = 0.0014). Down-regulation of ANXA10 was twofold more frequent in large than small HCCs (P = 0.0012), in grade II to III than grade I HCC (P <0.00001), and in stage IIIA to IV than stage I to II HCC (P <0.00001). Moreover, ANXA10 down-regulation and p53 mutation acted synergistically toward high-grade (P <0.00001), high-stage HCC (P <0.00001), and poorer prognosis (P = 0.0025). Our results indicate that the expression of the tissue- and tumor-restricted ANXA10 is a marker of liver cell differentiation and growth arrest, and its down-regulation associated with malignant phenotype of hepatocytes, vascular invasion, and progression of HCC, leading to poor prognosis. Thus, ANXA10 might serve as a new potential target of gene therapy for HCC.

Original languageEnglish
Pages (from-to)1831-1837
Number of pages7
JournalAmerican Journal of Pathology
Volume160
Issue number5
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Annexins
antineoplaston A10
Blood Vessels
Hepatocellular Carcinoma
Down-Regulation
Recurrence
Mutation
Biological Phenomena
Messenger RNA
Calcium-Binding Proteins
Cholangiocarcinoma
Liver
Genetic Therapy
Cell Differentiation
Hepatocytes
Neoplasms
Fetus
Carcinoma
Phenotype
Growth

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. / Liu, Shu Hsiang; Lin, Chiao Ying; Peng, Shian Yang; Jeng, Yung Ming; Pan, Hung Wei; Lai, Po Lin; Liu, Chao Lien; Hsu, Hey Chi.

In: American Journal of Pathology, Vol. 160, No. 5, 2002, p. 1831-1837.

Research output: Contribution to journalArticle

Liu, Shu Hsiang ; Lin, Chiao Ying ; Peng, Shian Yang ; Jeng, Yung Ming ; Pan, Hung Wei ; Lai, Po Lin ; Liu, Chao Lien ; Hsu, Hey Chi. / Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. In: American Journal of Pathology. 2002 ; Vol. 160, No. 5. pp. 1831-1837.
@article{d76c3391edae4849876b182dd9ee9a36,
title = "Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation",
abstract = "Annexins (ANXs) are a large group of calcium-binding proteins participating in diverse important biological processes. ANXA10 is the least expressed new member of unknown function. We showed that ANXA10 mRNA was expressed in adult liver and hepatocellular carcinoma (HCC), but not in multiple adult and fetal tissues, cholangiocarcinoma, and several other common carcinomas. Of 182 unifocal primary HCCs, ANXA10 mRNA was dramatically reduced in 121 (66{\%}), and the down-regulation correlated with p53 mutation (P = 0.024), early intrahepatic tumor recurrence (P = 0.0007), and lower 4-year survival (P = 0.0014). Down-regulation of ANXA10 was twofold more frequent in large than small HCCs (P = 0.0012), in grade II to III than grade I HCC (P <0.00001), and in stage IIIA to IV than stage I to II HCC (P <0.00001). Moreover, ANXA10 down-regulation and p53 mutation acted synergistically toward high-grade (P <0.00001), high-stage HCC (P <0.00001), and poorer prognosis (P = 0.0025). Our results indicate that the expression of the tissue- and tumor-restricted ANXA10 is a marker of liver cell differentiation and growth arrest, and its down-regulation associated with malignant phenotype of hepatocytes, vascular invasion, and progression of HCC, leading to poor prognosis. Thus, ANXA10 might serve as a new potential target of gene therapy for HCC.",
author = "Liu, {Shu Hsiang} and Lin, {Chiao Ying} and Peng, {Shian Yang} and Jeng, {Yung Ming} and Pan, {Hung Wei} and Lai, {Po Lin} and Liu, {Chao Lien} and Hsu, {Hey Chi}",
year = "2002",
language = "English",
volume = "160",
pages = "1831--1837",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation

AU - Liu, Shu Hsiang

AU - Lin, Chiao Ying

AU - Peng, Shian Yang

AU - Jeng, Yung Ming

AU - Pan, Hung Wei

AU - Lai, Po Lin

AU - Liu, Chao Lien

AU - Hsu, Hey Chi

PY - 2002

Y1 - 2002

N2 - Annexins (ANXs) are a large group of calcium-binding proteins participating in diverse important biological processes. ANXA10 is the least expressed new member of unknown function. We showed that ANXA10 mRNA was expressed in adult liver and hepatocellular carcinoma (HCC), but not in multiple adult and fetal tissues, cholangiocarcinoma, and several other common carcinomas. Of 182 unifocal primary HCCs, ANXA10 mRNA was dramatically reduced in 121 (66%), and the down-regulation correlated with p53 mutation (P = 0.024), early intrahepatic tumor recurrence (P = 0.0007), and lower 4-year survival (P = 0.0014). Down-regulation of ANXA10 was twofold more frequent in large than small HCCs (P = 0.0012), in grade II to III than grade I HCC (P <0.00001), and in stage IIIA to IV than stage I to II HCC (P <0.00001). Moreover, ANXA10 down-regulation and p53 mutation acted synergistically toward high-grade (P <0.00001), high-stage HCC (P <0.00001), and poorer prognosis (P = 0.0025). Our results indicate that the expression of the tissue- and tumor-restricted ANXA10 is a marker of liver cell differentiation and growth arrest, and its down-regulation associated with malignant phenotype of hepatocytes, vascular invasion, and progression of HCC, leading to poor prognosis. Thus, ANXA10 might serve as a new potential target of gene therapy for HCC.

AB - Annexins (ANXs) are a large group of calcium-binding proteins participating in diverse important biological processes. ANXA10 is the least expressed new member of unknown function. We showed that ANXA10 mRNA was expressed in adult liver and hepatocellular carcinoma (HCC), but not in multiple adult and fetal tissues, cholangiocarcinoma, and several other common carcinomas. Of 182 unifocal primary HCCs, ANXA10 mRNA was dramatically reduced in 121 (66%), and the down-regulation correlated with p53 mutation (P = 0.024), early intrahepatic tumor recurrence (P = 0.0007), and lower 4-year survival (P = 0.0014). Down-regulation of ANXA10 was twofold more frequent in large than small HCCs (P = 0.0012), in grade II to III than grade I HCC (P <0.00001), and in stage IIIA to IV than stage I to II HCC (P <0.00001). Moreover, ANXA10 down-regulation and p53 mutation acted synergistically toward high-grade (P <0.00001), high-stage HCC (P <0.00001), and poorer prognosis (P = 0.0025). Our results indicate that the expression of the tissue- and tumor-restricted ANXA10 is a marker of liver cell differentiation and growth arrest, and its down-regulation associated with malignant phenotype of hepatocytes, vascular invasion, and progression of HCC, leading to poor prognosis. Thus, ANXA10 might serve as a new potential target of gene therapy for HCC.

UR - http://www.scopus.com/inward/record.url?scp=0036092297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036092297&partnerID=8YFLogxK

M3 - Article

VL - 160

SP - 1831

EP - 1837

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 5

ER -